Analysts expect that Syros Pharmaceuticals Inc (NASDAQ:SYRS) will post earnings per share (EPS) of ($0.45) for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for Syros Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.49) and the highest is ($0.43). Syros Pharmaceuticals posted earnings per share of ($0.53) during the same quarter last year, which would indicate a positive year-over-year growth rate of 15.1%. The company is expected to announce its next earnings report on Wednesday, November 14th.

On average, analysts expect that Syros Pharmaceuticals will report full-year earnings of ($1.85) per share for the current year, with EPS estimates ranging from ($1.92) to ($1.77). For the next financial year, analysts expect that the business will post earnings of ($1.93) per share, with EPS estimates ranging from ($2.12) to ($1.67). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that that provide coverage for Syros Pharmaceuticals.

Syros Pharmaceuticals (NASDAQ:SYRS) last issued its earnings results on Friday, August 10th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.50) by $0.07. The company had revenue of $0.38 million for the quarter, compared to analysts’ expectations of $1.33 million.

A number of analysts recently weighed in on the stock. HC Wainwright reaffirmed a “hold” rating and issued a $10.00 price objective on shares of Syros Pharmaceuticals in a research note on Wednesday, August 8th. BidaskClub raised shares of Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, August 31st. ValuEngine lowered shares of Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, June 18th. Zacks Investment Research raised shares of Syros Pharmaceuticals from a “hold” rating to a “buy” rating and set a $13.00 price objective for the company in a research note on Friday, August 10th. Finally, Cann reaffirmed a “buy” rating and issued a $26.00 price objective on shares of Syros Pharmaceuticals in a research note on Tuesday, August 7th. One research analyst has rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $19.29.

A number of institutional investors have recently made changes to their positions in SYRS. BlackRock Inc. raised its holdings in Syros Pharmaceuticals by 70.4% in the second quarter. BlackRock Inc. now owns 1,583,631 shares of the company’s stock worth $16,169,000 after purchasing an additional 654,094 shares in the last quarter. ARK Investment Management LLC raised its holdings in Syros Pharmaceuticals by 19.6% in the second quarter. ARK Investment Management LLC now owns 1,799,553 shares of the company’s stock worth $18,373,000 after purchasing an additional 294,663 shares in the last quarter. Millennium Management LLC raised its holdings in Syros Pharmaceuticals by 129.3% in the second quarter. Millennium Management LLC now owns 375,466 shares of the company’s stock worth $3,834,000 after purchasing an additional 211,696 shares in the last quarter. Point72 Asset Management L.P. bought a new position in Syros Pharmaceuticals in the second quarter worth about $1,703,000. Finally, Renaissance Technologies LLC bought a new position in Syros Pharmaceuticals in the second quarter worth about $1,684,000. Institutional investors and hedge funds own 60.70% of the company’s stock.

Shares of SYRS traded down $0.27 during trading hours on Friday, reaching $7.61. 179,167 shares of the company traded hands, compared to its average volume of 187,573. The firm has a market capitalization of $400.82 million, a P/E ratio of -3.57 and a beta of -1.96. Syros Pharmaceuticals has a 12-month low of $6.30 and a 12-month high of $17.50.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian cancer, breast cancer, and AML.

Further Reading: Investing in Dividend Stocks

Get a free copy of the Zacks research report on Syros Pharmaceuticals (SYRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.